Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
iCAD Inc (NASDAQ: ICAD) delivers AI-powered medical imaging solutions that transform cancer detection through advanced analytics. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s innovations in early diagnosis technology.
Access official announcements covering regulatory milestones, clinical study results, and strategic partnerships. Stay informed about developments in mammography AI systems, radiation therapy advancements, and global market expansions. Our curated repository ensures timely access to earnings reports, product launch details, and industry recognition updates.
Key content categories include FDA clearances for new AI algorithms, collaborations with radiology networks, and enhancements to the ProFound Breast Health Suite. Bookmark this page for direct access to primary sources about iCAD’s contributions to precision medicine and workflow optimization technologies.
iCAD has partnered with Microsoft to integrate its AI-powered mammography solutions into Microsoft's Precision Imaging Network (PIN). The collaboration enables automated patient reporting through PowerScribe integration, connecting over 17,000 healthcare facilities nationwide.
Key highlights:
- ProFound AI Breast Health Suite will be cloud-hosted on Microsoft's network, offering streamlined AI-driven insights for breast health detection
- The recently FDA-cleared ProFound Detection Version 4.0 shows 22% improvement in detecting complex cancer subtypes and 18% reduction in false positives
- The integration supports iCAD's transition to a SaaS model while expanding market reach
- The solution incorporates prior mammograms into AI analysis for better assessment of changes over time
The technology will be showcased at the SIIM25 Annual Meeting + InformaticsTECH Expo in Portland from May 21-23, 2025.
iCAD (NASDAQ: ICAD) has appointed Mark Koeniguer as Chief Commercial Officer (CCO) to spearhead global growth initiatives. Koeniguer, who brings over 30 years of experience in MedTech, AI, and digital health, will oversee commercial sales teams, partnerships, operations, and customer success.
Most recently as CEO of ScreenPoint Medical, Koeniguer achieved a 400% increase in annual recurring revenue and launched two FDA-cleared products. His previous executive roles include positions at Riverain Technologies, Volpara Health, R2 Technology, Stereotaxis, and GE Healthcare.
In his new role at iCAD, a provider of AI-powered breast health solutions, Koeniguer will focus on revenue growth across North America and globally, leveraging his extensive experience in the medical imaging field and software as a medical device (SaMD) space.
iCAD (NASDAQ: ICAD) reported its Q4 and full-year 2024 financial results, showing positive momentum in its SaaS transition. Q4 highlights include:
- Total revenue increased 14% to $5.4 million
- Annual Recurring Revenue (ARR) grew 11% to $9.8 million
- Gross Profit Margin of 86%
- 382 total deals closed in 2024, including 42 ProFound Cloud deals
The company secured FDA clearance for ProFound Detection V4.0 and expanded globally with new distribution agreements in South Africa, Portugal, and the UK. For full-year 2024, revenue reached $19.6 million, up 13% year-over-year, with a gross profit margin of 85%. The company reported a net loss of ($5.6) million or ($0.21) per share for 2024, improved from ($7.0) million in 2023. Cash position stands at $17.2 million, which management believes sufficient for at least 12 months of operations.
iCAD (NASDAQ: ICAD), a global leader in AI-powered cancer detection solutions, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 19, 2025, after market close. The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results. Investors can access the call through toll-free (877-545-0523) or international (973-528-0016) numbers using participant code 174549, or via webcast.
iCAD (NASDAQ: ICAD) and RamSoft have announced a strategic commercial preferred distributor and integration partnership across the US and Canada. The collaboration will integrate iCAD's ProFound AI® Breast Health Suite into RamSoft's cloud-based RIS/PACS platform, serving over 750 sites worldwide.
The partnership aims to enhance workflow efficiency and diagnostic confidence in breast cancer detection. Mammolink will be the first organization to implement the integrated solution. The ProFound AI technology addresses the challenge of 20-40% of breast cancers remaining undetected by traditional screening mammography.
The integration will be available through RamSoft's PowerServer platform, which is FDA 510(k) cleared and IHE mammo profile compliant. The system features customizable layouts, MG CAD Markers support, and digital breast tomosynthesis (DBT) capabilities, streamlining workflow and improving diagnostic efficiency.
iCAD (NASDAQ: ICAD) and Koios Medical have announced a strategic reseller partnership to deliver an integrated AI-powered breast cancer detection solution. The collaboration combines iCAD's ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, creating a comprehensive multi-modality AI suite.
The partnership aims to streamline AI implementation across both mammography and breast ultrasound, providing radiologists with an enhanced workflow from screening to diagnosis. Koios SmartUltrasound is an AI-based platform designed to detect and diagnose thyroid and breast cancers in ultrasound exams, improving interpretation speed and reducing unnecessary surgical procedures.
Both companies will showcase their integrated solution at ECR 2025 in Vienna, Austria, from February 26 to March 2, 2025.
iCAD announced five clinical presentations and abstracts at the European Congress of Radiology (ECR) 2025, highlighting advancements in breast cancer detection, risk evaluation, and breast arterial calcification assessment. The presentations, scheduled from February 26 to March 2, 2025, in Vienna, will showcase research on AI-powered solutions for personalized risk assessment and early detection.
The company will present its new ProFound Cloud, a SaaS platform designed to deliver advanced AI solutions to healthcare providers globally. The presentations include studies on a 10-year image-derived AI risk model, optimal utilization of AI diagnostic software in mammography screening, short-term risk prediction comparisons, and workflow optimization in breast screening programs.
iCAD will demonstrate its latest innovations at booth AI-27, including the ProFound suite of solutions for DBT Detection, 2D Detection, Density Assessment, and Risk.
iCAD has released preliminary, unaudited financial results for Q4 2024. The company expects total revenue to be between $5.1 million and $5.3 million. Total Annual Recurring Revenue (T-ARR) reached $9.8 million, showing an 11% year-over-year increase.
During Q4 2024, iCAD closed 106 deals, including 19 cloud deals with both new and existing customers. The company will participate in the BTIG at Snowbird Conference from February 11-12, 2025, where management will hold one-on-one meetings with investors. The full audited results for Q4 and year-end 2024 will be announced in March 2025.
iCAD announced four AI-driven breast cancer research abstracts presented at the 2024 San Antonio Breast Cancer Symposium. The studies focus on ProFound AI Breast Health Suite and its applications in breast cancer detection and risk assessment across diverse populations.
Key findings include: higher prevalence of Breast Arterial Calcifications (BAC) in breast cancer patients, suggesting potential need for cardiovascular assessment; effectiveness of AI-driven short-term breast cancer risk assessment across racial groups and breast densities; and superior performance of a 10-year image-derived AI-risk model compared to the clinical Tyrer-Cuzick v8 model. The AI risk model identified 32% of breast cancers in 9.7% of women classified as high-risk.
iCAD announces significant developments at RSNA 2024, including its FDA-cleared ProFound Detection Version 4.0 and a new partnership with Cascaid Health. The collaboration will launch ProFound Health in Q1 2025, offering virtual second reads of mammograms using AI technology to enhance breast cancer detection.
The new ProFound Detection Version 4.0 improves aggressive cancer detection by 22% and reduces cases with no marks by 18%. Clinical results show a 23% increase in overall cancer detection rates, 32% enhanced detection in dense breast tissue, and a 12% reduction in invasive cancer size.
The company is showcasing these innovations at RSNA 2024 in Chicago (December 1-5), featuring presentations on real-world AI implementation results and advances in calcification detection. The initiative aims to democratize access to AI-powered mammography and improve breast cancer detection outcomes.
FAQ
What is the current stock price of Icad (ICAD)?
What is the market cap of Icad (ICAD)?
